Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Cell Mol Life Sci ; 81(1): 234, 2024 May 24.
Artículo en Inglés | MEDLINE | ID: mdl-38789799

RESUMEN

Vanishing white matter (VWM) is a leukodystrophy caused by biallelic pathogenic variants in eukaryotic translation initiation factor 2B. To date, it remains unclear which factors contribute to VWM pathogenesis. Here, we investigated the basis of VWM pathogenesis using the 2b5ho mouse model. We first mapped the temporal proteome in the cerebellum, corpus callosum, cortex, and brainstem of 2b5ho and wild-type (WT) mice. Protein changes observed in 2b5ho mice were then cross-referenced with published proteomic datasets from VWM patient brain tissue to define alterations relevant to the human disease. By comparing 2b5ho mice with their region- and age-matched WT counterparts, we showed that the proteome in the cerebellum and cortex of 2b5ho mice was already dysregulated prior to pathology development, whereas proteome changes in the corpus callosum only occurred after pathology onset. Remarkably, protein changes in the brainstem were transient, indicating that a compensatory mechanism might occur in this region. Importantly, 2b5ho mouse brain proteome changes reflect features well-known in VWM. Comparison of the 2b5ho mouse and VWM patient brain proteomes revealed shared changes. These could represent changes that contribute to the disease or even drive its progression in patients. Taken together, we show that the 2b5ho mouse brain proteome is affected in a region- and time-dependent manner. We found that the 2b5ho mouse model partly replicates the human disease at the protein level, providing a resource to study aspects of VWM pathogenesis by highlighting alterations from early to late disease stages, and those that possibly drive disease progression.


Asunto(s)
Modelos Animales de Enfermedad , Leucoencefalopatías , Proteoma , Proteómica , Sustancia Blanca , Animales , Ratones , Humanos , Proteoma/metabolismo , Leucoencefalopatías/metabolismo , Leucoencefalopatías/genética , Leucoencefalopatías/patología , Sustancia Blanca/metabolismo , Sustancia Blanca/patología , Cuerpo Calloso/metabolismo , Cuerpo Calloso/patología , Factor 2B Eucariótico de Iniciación/metabolismo , Factor 2B Eucariótico de Iniciación/genética , Encéfalo/metabolismo , Encéfalo/patología , Ratones Endogámicos C57BL , Cerebelo/metabolismo , Cerebelo/patología
2.
Acta Neuropathol ; 143(2): 159-177, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34878591

RESUMEN

Astrocytes regulate central nervous system development, maintain its homeostasis and orchestrate repair upon injury. Emerging evidence support functional specialization of astroglia, both between and within brain regions. Different subtypes of gray matter astrocytes have been identified, yet molecular and functional diversity of white matter astrocytes remains largely unexplored. Nonetheless, their important and diverse roles in maintaining white matter integrity and function are well recognized. Compelling evidence indicate that impairment of normal astrocytic function and their response to injury contribute to a wide variety of diseases, including white matter disorders. In this review, we highlight our current understanding of astrocyte heterogeneity in the white matter of the mammalian brain and how an interplay between developmental origins and local environmental cues contribute to astroglial diversification. In addition, we discuss whether, and if so, how, heterogeneous astrocytes could contribute to white matter function in health and disease and focus on the sparse human research data available. We highlight four leukodystrophies primarily due to astrocytic dysfunction, the so-called astrocytopathies. Insight into the role of astroglial heterogeneity in both healthy and diseased white matter may provide new avenues for therapies aimed at promoting repair and restoring normal white matter function.


Asunto(s)
Astrocitos/citología , Encéfalo/citología , Sustancia Blanca/citología , Humanos
3.
Neurobiol Aging ; 140: 102-115, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38763075

RESUMEN

Astrocyte heterogeneity and its relation to aging in the normal human brain remain poorly understood. We here analyzed astrocytes in gray and white matter brain tissues obtained from donors ranging in age between the neonatal period to over 100 years. We show that astrocytes are differently distributed with higher density in the white matter. This regional difference in cellular density becomes less prominent with age. Additionally, we confirm the presence of morphologically distinct astrocytes, with gray matter astrocytes being morphologically more complex. Notably, gray matter astrocytes morphologically change with age, while white matter astrocytes remain relatively consistent in morphology. Using regional mass spectrometry-based proteomics, we did, however, identify astrocyte specific proteins with regional differences in abundance, reflecting variation in cellular density or expression level. Importantly, the expression of some astrocyte specific proteins region-dependently decreases with age. Taken together, we provide insights into region- and age-related differences in astrocytes in the human brain.


Asunto(s)
Envejecimiento , Astrocitos , Sustancia Gris , Sustancia Blanca , Humanos , Astrocitos/patología , Astrocitos/metabolismo , Envejecimiento/patología , Envejecimiento/fisiología , Sustancia Gris/patología , Sustancia Gris/citología , Adulto , Anciano , Sustancia Blanca/patología , Sustancia Blanca/citología , Adulto Joven , Persona de Mediana Edad , Anciano de 80 o más Años , Niño , Lactante , Preescolar , Adolescente , Recién Nacido , Encéfalo/citología , Encéfalo/patología , Encéfalo/metabolismo , Proteómica , Masculino , Femenino , Recuento de Células
4.
Acta Neuropathol Commun ; 11(1): 103, 2023 06 22.
Artículo en Inglés | MEDLINE | ID: mdl-37349783

RESUMEN

Vanishing white matter (VWM) is a leukodystrophy that primarily manifests in young children. In this disease, the brain white matter is differentially affected in a predictable pattern with telencephalic brain areas being most severely affected, while others remain allegedly completely spared. Using high-resolution mass spectrometry-based proteomics, we investigated the proteome patterns of the white matter in the severely affected frontal lobe and normal appearing pons in VWM and control cases to identify molecular bases underlying regional vulnerability. By comparing VWM patients to controls, we identified disease-specific proteome patterns. We showed substantial changes in both the VWM frontal and pons white matter at the protein level. Side-by-side comparison of brain region-specific proteome patterns further revealed regional differences. We found that different cell types were affected in the VWM frontal white matter than in the pons. Gene ontology and pathway analyses identified involvement of region specific biological processes, of which pathways involved in cellular respiratory metabolism were overarching features. In the VWM frontal white matter, proteins involved in glycolysis/gluconeogenesis and metabolism of various amino acids were decreased compared to controls. By contrast, in the VWM pons white matter, we found a decrease in proteins involved in oxidative phosphorylation. Taken together, our data show that brain regions are affected in parallel in VWM, but to different degrees. We found region-specific involvement of different cell types and discovered that cellular respiratory metabolism is likely to be differentially affected across white matter regions in VWM. These region-specific changes help explain regional vulnerability to pathology in VWM.


Asunto(s)
Leucoencefalopatías , Sustancia Blanca , Niño , Humanos , Preescolar , Sustancia Blanca/patología , Leucoencefalopatías/patología , Proteoma/metabolismo , Encéfalo/patología , Fosforilación Oxidativa
5.
Cells ; 11(22)2022 11 12.
Artículo en Inglés | MEDLINE | ID: mdl-36429009

RESUMEN

Vanishing white matter (VWM) is classified as a leukodystrophy with astrocytes as primary drivers in its pathogenesis. Magnetic resonance imaging has documented the progressive thinning of cortices in long-surviving patients. Routine histopathological analyses, however, have not yet pointed to cortical involvement in VWM. Here, we provide a comprehensive analysis of the VWM cortex. We employed high-resolution-mass-spectrometry-based proteomics and immunohistochemistry to gain insight into possible molecular disease mechanisms in the cortices of VWM patients. The proteome analysis revealed 268 differentially expressed proteins in the VWM cortices compared to the controls. A majority of these proteins formed a major protein interaction network. A subsequent gene ontology analysis identified enrichment for terms such as cellular metabolism, particularly mitochondrial activity. Importantly, some of the proteins with the most prominent changes in expression were found in astrocytes, indicating cortical astrocytic involvement. Indeed, we confirmed that VWM cortical astrocytes exhibit morphological changes and are less complex in structure than control cells. Our findings also suggest that these astrocytes are immature and not reactive. Taken together, we provide insights into cortical involvement in VWM, which has to be taken into account when developing therapeutic strategies.


Asunto(s)
Leucoencefalopatías , Sustancia Blanca , Humanos , Sustancia Blanca/patología , Leucoencefalopatías/genética , Astrocitos/metabolismo , Proteómica , Mitocondrias/metabolismo
6.
J Control Release ; 286: 114-124, 2018 09 28.
Artículo en Inglés | MEDLINE | ID: mdl-30026082

RESUMEN

Degeneration of dopamine (DA) neurons in the substantia nigra pars compacta is the pathological hallmark of Parkinson's disease (PD). In PD multiple pathogenic mechanisms initiate and drive this neurodegenerative process, making the development of effective treatments challenging. To date, PD patients are primarily treated with dopaminergic drugs able to temporarily enhance DA levels, therefore relieving motor symptoms. However, the drawbacks of these therapies including the inability to alter disease progression are constantly supporting the search for alternative treatment approaches. Over the past years efforts have been put into the development of new therapeutic strategies based on the delivery of therapeutic genes using viral vectors or transplantation of DA neurons for cell-based DA replacement. Here, past achievements and recent advances in gene- and cell-based therapies for PD are outlined. We discuss how current gene and cell therapy strategies hold great promise for the treatment of PD and how the use of stem cells and recent developments in cellular reprogramming could contribute to open a new avenue in PD therapy.


Asunto(s)
Técnicas de Reprogramación Celular/métodos , Terapia Genética/métodos , Enfermedad de Parkinson/terapia , Animales , Astrocitos/citología , Astrocitos/metabolismo , Astrocitos/trasplante , Reprogramación Celular , Dopamina/genética , Dopamina/metabolismo , Neuronas Dopaminérgicas/citología , Neuronas Dopaminérgicas/metabolismo , Neuronas Dopaminérgicas/trasplante , Humanos , Microglía/citología , Microglía/metabolismo , Microglía/trasplante , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/metabolismo
7.
Eur Neuropsychopharmacol ; 28(1): 171-184, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-29153928

RESUMEN

Motivational deficits are a key symptom in multiple psychiatric disorders, including major depressive disorder, schizophrenia and addiction. A likely neural substrate for these motivational deficits is the brain dopamine (DA) system. In particular, DA signalling in the nucleus accumbens, which originates from DA neurons in the ventral tegmental area (VTA), has been identified as a crucial substrate for effort-related and activational aspects of motivation. Unravelling how VTA DA neuronal activity relates to motivational behaviours is required to understand how motivational deficits in psychiatry can be specifically targeted. In this study, we therefore used designer receptors exclusively activated by designer drugs (DREADD) in TH:Cre rats, in order to determine the effects of chemogenetic DA neuron activation on different aspects of motivational behaviour. We found that chemogenetic activation of DA neurons in the VTA, but not substantia nigra, significantly increased responding for sucrose under a progressive ratio schedule of reinforcement. More specifically, high effort exertion was characterized by increased initiations of reward-seeking actions. This effect was dependent on effort requirements and instrumental contingencies, but was not affected by sucrose pre-feeding. Together, these findings indicate that VTA DA neuronal activation drives motivational behaviour by facilitating action initiation. With this study, we show that enhancing excitability of VTA DA neurons is a viable strategy to improve motivational behaviour.


Asunto(s)
Conducta Animal/fisiología , Neuronas Dopaminérgicas/fisiología , Motivación/fisiología , Sustancia Negra/fisiología , Área Tegmental Ventral/fisiología , Animales , Conducta Animal/efectos de los fármacos , Clozapina/análogos & derivados , Drogas de Diseño , Neuronas Dopaminérgicas/citología , Neuronas Dopaminérgicas/efectos de los fármacos , Masculino , Motivación/efectos de los fármacos , Ratas Long-Evans , Ratas Transgénicas , Refuerzo en Psicología , Sustancia Negra/citología , Sustancia Negra/efectos de los fármacos , Área Tegmental Ventral/citología , Área Tegmental Ventral/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA